Bridgeway Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Bridgeway Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Buy	+45,000	New	+$363K	﹤0.01%	1006
2024 Q3	–	Sell	-21,920	Closed	-$379K	–	1326
2024 Q2	$379K	Hold	21,920	–	–	0.01%	922
2024 Q1	$489K	Sell	21,920 -2,759	-11%	-$57.4K	0.01%	938
2023 Q4	$453K	Hold	24,679	–	–	0.01%	965
2023 Q3	$428K	Buy	24,679 +6,058	+33%	+$105K	0.01%	924
2023 Q2	$339K	Sell	18,621 -208	-1%	-$4.16K	0.01%	1015
2023 Q1	$323K	Buy	18,829 +186	+1%	+$3.01K	0.01%	990
2022 Q4	$433K	Buy	18,643 +2,429	+15%	+$56.3K	0.01%	914
2022 Q3	$360K	Buy	+16,214	New	+$386K	0.01%	980

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Bridgeway Capital Management's LENZ Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 45,000 shares worth $256K. The stake represents ﹤0.01% of the portfolio and ranks #1006 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in LENZ as recently as Q2 2024.

Bridgeway Capital Management first reported a position in LENZ in Q3 2022 and has held it in 9 quarters since. The position peaked at $489K in Q1 2024. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Bridgeway Capital Management held 45,000 shares of LENZ Therapeutics worth $256K as of Q2 2026.
LENZ Therapeutics was a new Bridgeway Capital Management position in Q2 2026.
LENZ Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1006 holding.
Bridgeway Capital Management first reported a position in LENZ Therapeutics in Q3 2022 and has held it in 9 quarters since.
Bridgeway Capital Management's LENZ Therapeutics position peaked at $489K in Q1 2024.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.